title: [New therapies in ophthalmology: inhibitors of cytokines and chemokines: new treatment perspectives].
abstract: Anti-TNF-alpha (infliximab and etanercept) are potent, selective inhibitors of the inflammatory cascade. They have been widely used in the therapy of rheumatoid arthritis, Crohn's disease and psoriasis. Their efficacy in ophthalmology has been recently proven. The wide use of cytokines inhibitors could also be very useful in the therapy of neovessels in macular degeneration age-related, since the role of inflammation in the proliferation of neovessels has been recently discovered.
authors.affiliation: Hôpital ophtalmique Jules Gonin, Université de Lausanne, 15, avenue de France, 1004 Lausanne. yan.guex@ophtal.vd.ch
authors.forename: Y
authors.initials: Y
authors.lastname: Guex-Crosier
authors.forename: L
authors.initials: L
authors.lastname: Zografos
mesh_terms: D018925:Chemokines / Q000037:antagonists & inhibitors; D016207:Cytokines / Q000037:antagonists & inhibitors; D005128:Eye Diseases / Q000188:drug therapy*; D006801:Humans; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D018925:Chemokines; D016207:Cytokines; D014409:Tumor Necrosis Factor-alpha